A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

Lloyd Minor, MD, the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, will discuss “Digitally Driven: Health Care in the Era of Precision Health,” during a Flexner Discovery Lecture on Thusday, Feb. 21.

Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.

For much of her career, Angelika Amon, PhD, recipient of the 2018 Vanderbilt Prize in Biomedical Science, has pursued a mystery with life-or-death consequences.

Vanderbilt investigators have discovered that certain microRNAs — "telegram"-like signals — increase after the induction of allergic airway inflammation.

Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.